Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin
暂无分享,去创建一个
L. Fink | M. Boerma | M. Hauer-Jensen | J. Ellis | A. Bartolozzi | S. McGonigle | Q. Fu | M. Vozenin-Brotons | Junru Wang | P. Sweetnam | D. Loose | Elsa Paradise | J. L. Ellis
[1] Chryso Kanthou,et al. Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability. , 2007, International journal of radiation oncology, biology, physics.
[2] J. Bourhis,et al. Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in Rats , 2007, Clinical Cancer Research.
[3] L. Fink,et al. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. , 2007, International journal of radiation oncology, biology, physics.
[4] R. Schwartz,et al. Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. , 2006, Journal of the American Society of Nephrology : JASN.
[5] G. Shen,et al. Statins for diabetic cardiovascular complications. , 2006, Current vascular pharmacology.
[6] K. Dawson,et al. TGF-β1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells , 2006 .
[7] R. Sheppard,et al. Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.
[8] L. Fink,et al. Comparative expression profiling in primary and immortalized endothelial cells: changes in gene expression in response to hydroxy methylglutaryl-coenzyme A reductase inhibition , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[9] B. Kaina,et al. Rho GTPases: promising cellular targets for novel anticancer drugs. , 2006, Current cancer drug targets.
[10] K. Dawson,et al. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. , 2006, Vascular pharmacology.
[11] James Q. Yin,et al. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. , 2006, Liver international : official journal of the International Association for the Study of the Liver.
[12] A. Takeshita,et al. Rho-kinase is an important therapeutic target in cardiovascular medicine. , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[13] J. Liao,et al. Rho GTPases, statins, and nitric oxide. , 2005, Circulation research.
[14] R. Sacco,et al. Drug Insight: statins and stroke , 2005, Nature Clinical Practice Cardiovascular Medicine.
[15] Alan Hall,et al. Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.
[16] J. Bourhis,et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] J. Couchman,et al. The Rho kinases I and II regulate different aspects of myosin II activity , 2005, The Journal of cell biology.
[18] H. Christensen,et al. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC–tandem MS , 2005, Analytical and bioanalytical chemistry.
[19] Helmut Mack,et al. Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.
[20] J. Bourhis,et al. An unusual cause of upper gastrointestinal haemorrhage , 2005, Gut.
[21] M. Spiteri,et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. , 2005, American journal of respiratory cell and molecular biology.
[22] Philippe Rigault,et al. A novel, high-performance random array platform for quantitative gene expression profiling. , 2004, Genome research.
[23] S. Harvey,et al. Downstream effects of ROCK signaling in cultured human corneal stromal cells: microarray analysis of gene expression. , 2004, Investigative ophthalmology & visual science.
[24] T. Moriyama,et al. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. , 2004, Drug news & perspectives.
[25] T. Kodama,et al. Global analysis of RNA expression profile in human vascular cells treated with statins. , 2004, Journal of atherosclerosis and thrombosis.
[26] J. Mehta,et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[27] S. Horie,et al. Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[28] H. Lennernäs. Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.
[29] G. Maurer,et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins , 2002, British journal of pharmacology.
[30] M. Goppelt‐Struebe,et al. Rho‐dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) , 2001, British journal of pharmacology.
[31] J. Lankelma,et al. Simvastatin Improves Disturbed Endothelial Barrier Function , 2000, Circulation.
[32] V. Koteliansky,et al. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. , 2000, Gastroenterology.
[33] M. Dake,et al. Thrombomodulin overexpression to limit neointima formation. , 2000, Circulation.
[34] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[35] J. Navarro-Antolín,et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. , 1998, The Journal of clinical investigation.
[36] K. Takatsuki,et al. rhs-TM prevents ET-induced increase in pulmonary vascular permeability through protein C activation. , 1997, American journal of physiology. Lung cellular and molecular physiology.